144 related articles for article (PubMed ID: 17644742)
1. Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis.
Calvez T; Laurian Y; Goudemand J
Blood; 2007 Aug; 110(3):1073-4; author reply 1074-5. PubMed ID: 17644742
[No Abstract] [Full Text] [Related]
2. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
[No Abstract] [Full Text] [Related]
3. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
Kallas A; Kuuse S; Maimets T; Pooga M
Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
[No Abstract] [Full Text] [Related]
4. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
[No Abstract] [Full Text] [Related]
5. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.
Kaveri S; Gringeri A; Heisel-Kurth M; Kreuz W
Haemophilia; 2009 Mar; 15(2):587-91. PubMed ID: 19347997
[No Abstract] [Full Text] [Related]
7. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
[No Abstract] [Full Text] [Related]
8. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
9. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S; Jiménez-Yuste V; Santagostino E
Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
[No Abstract] [Full Text] [Related]
10. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
Berntorp E
Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
[TBL] [Abstract][Full Text] [Related]
11. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
[TBL] [Abstract][Full Text] [Related]
12. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
13. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor development.
Astermark J; Lacroix-Desmazes S; Reding MT
Haemophilia; 2008 Jul; 14 Suppl 3():36-42. PubMed ID: 18510520
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
16. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
Ettingshausen CE; Kreuz W
Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
[TBL] [Abstract][Full Text] [Related]
17. Factor VIII/von Willebrand factor. Structure and function.
Zimmerman TS
Ann N Y Acad Sci; 1987; 509():53-9. PubMed ID: 2447817
[No Abstract] [Full Text] [Related]
18. Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
Ewenstein BM; Reininger AJ
Haemophilia; 2011 Sep; 17(5):e847-8. PubMed ID: 21752157
[No Abstract] [Full Text] [Related]
19. The factor VIII complex: structure and function.
Hoyer LW
Prog Clin Biol Res; 1981; 72():1-26. PubMed ID: 6801681
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors in previously treated patients: a review of the literature.
Kempton CL
Haemophilia; 2010 May; 16(102):61-5. PubMed ID: 20536987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]